Document Detail


Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.
MedLine Citation:
PMID:  15293609     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study examined the effects of bronchodilator-induced reductions in lung hyperinflation on breathing pattern, ventilation and dyspnoea during exercise in chronic obstructive pulmonary disease (COPD). Quantitative tidal flow/volume loop analysis was used to evaluate abnormalities in dynamic ventilatory mechanics and their manipulation by a bronchodilator. In a randomised double-blind crossover study, 23 patients with COPD (mean +/- SEM forced expiratory volume in one second 42 +/- 3% of the predicted value) inhaled salmeterol 50 microg or placebo twice daily for 2 weeks each. After each treatment period, 2 h after dose, patients performed pulmonary function tests and symptom-limited cycle exercise at 75% of their maximal work-rate. After salmeterol versus placebo at rest, volume-corrected maximal expiratory flow rates increased by 175 +/- 52%, inspiratory capacity (IC) increased by 11 +/- 2% pred and functional residual capacity decreased by 11 +/- 3% pred. At a standardised time during exercise, salmeterol increased IC, tidal volume (VT), mean inspiratory and expiratory flows, ventilation, oxygen uptake (VO2) and carbon dioxide output. Salmeterol increased peak exercise endurance, VO2 and ventilation by 58 +/- 19, 8 +/- 3 and 12 +/- 3%, respectively. Improvements in peak VO2 correlated best with increases in peak VT; increases in peak VT and resting IC were interrelated. The reduction in dyspnoea ratings at a standardised time correlated with the increased VT. Mechanical factors play an important role in shaping the ventilatory response to exercise in chronic obstructive pulmonary disease. Bronchodilator-induced lung deflation reduced mechanical restriction, increased ventilatory capacity and decreased respiratory discomfort, thereby increasing exercise endurance.
Authors:
D E O'Donnell; N Voduc; M Fitzpatrick; K A Webb
Related Documents :
4708899 - Studies of the pulmonary vagal control of central respiratory rhythm in the absence of ...
2010409 - Respiratory adaptations to dead space loading during maximal incremental exercise.
8306029 - Bronchoconstriction occurring during exercise in asthmatic subjects.
11247949 - Role of nitric oxide during hyperventilation-induced bronchoconstriction in the guinea ...
22010599 - A long-term care facility pandemic influenza preparedness planning assessment tool.
2122169 - Using smoothing splines for detecting ventilatory thresholds.
12715969 - Habitual exercise and the age-associated decline in large artery compliance.
3534829 - Blood pressure response to dynamic exercise in healthy and hypertensive youths.
17153649 - Measuring early plaque formation clinically.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The European respiratory journal     Volume:  24     ISSN:  0903-1936     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2004 Jul 
Date Detail:
Created Date:  2004-08-05     Completed Date:  2005-03-10     Revised Date:  2013-05-23    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Denmark    
Other Details:
Languages:  eng     Pagination:  86-94     Citation Subset:  IM    
Affiliation:
Respiratory Investigation Unit, Dept of Medicine, Queen's University, Kingston, Canada. odonnell@post.queensu.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Aged
Airway Resistance / drug effects
Albuterol / administration & dosage*,  analogs & derivatives*
Bronchodilator Agents / administration & dosage*
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Exercise / physiology*
Female
Follow-Up Studies
Humans
Inspiratory Capacity / drug effects
Male
Middle Aged
Probability
Pulmonary Disease, Chronic Obstructive / diagnosis,  drug therapy*
Respiratory Function Tests
Risk Assessment
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 18559-94-9/Albuterol; 2I4BC502BT/salmeterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  STAT4 activation in smokers and patients with chronic obstructive pulmonary disease.
Next Document:  Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect.